Hematologist/Oncologist @TGHCares Cancer Institute. Trained @MoffittNews, @EmoryDeptofMed, @umiamimedicine. Interest in lymphoma. All tweets my own.
Tampa, FL
Joined September 2019
- Tweets197
- Following167
- Followers332
- Likes557
Nikesh Shah, MD retweeted
The SUNMO trial manuscript is now published at @JCO_ASCO! Mosun-Pola is superior to RGemOx in patients with ref/rel LBCL with 3X progression free survival and 2x complete response rates. Only 4% had CRS more than a fever. #lymsm
@elizabeth_budde
ascopubs.org/doi/10.1200/JCO…
Nikesh Shah, MD retweeted
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-cell Lymphoma: Primary Results of the Phase 3 SUNMO Trial. Co-authored by @Lymphoma_Doc
Read the full article brnw.ch/21wWoAi
#lymsm
Had a great time in Milano at EHA! Presented data from our novel program delivering inpatient-level care at home to patients with Heme malignancies. Proud to have multiple presentations from Tampa General Hospital Cancer Institute
Had a blast discussing CAR-T and bispecifics in lymphoma with Alan Kerr! Excited to bring these game changing therapies to our patients @TGHCares
An episode of MD Cast by Tampa General Hospital podcast is here! Titled "Immunotherapies in Lymphoma: CAR-T and Bispecific Antibodies," Dr. Nikesh Shah & Dr. D. Alan Kerr II join us from the TGH Cancer Institute to share expert insights. CME/CEU available: tgh.org/MDCast
Nikesh Shah, MD retweeted
Interesting study on burnout in hem/onc - working with APPs (not surprising!) and being young are protective but being female 💆🏻♀️ and RVU-only based compensation increase odds for burnout. ashpublications.org/bloodadv…
Glofitamab just approved in r/r DLBCL after 2 lines. Also requires hospitalization for full dose like Epco. Biggest difference is finite duration.
fda.gov/drugs/drug-approvals…
Epcoritamab just approved for r/r DLBCL! Very exciting to see how this will be implemented in the community prnewswire.com/news-releases…
Grateful to help grow the lymphoma program and build a mantle cell lymphoma center of excellence under the leadership of Dr. Eduardo Sotomayor @TGHCares Cancer Institute!
tgh.org/news/tgh-press-relea… #lymsm
Pola-R-CHP approved for DLBCL or HGBCL with IPI 2 or higher based on POLARIX data. Interesting since subgroup analysis showed less benefit for IPI 2, GCB, and double hit (of course not powered for this). Will you use universally for this population? Longer fu is crucial
#lymsm
Congratulations! Very well deserved!
Many congratulations to our very own associate PD Dr. Jaglal for being chosen @MoffittNews "Clinical Educator of the Year"!! His passion for teaching is inspirational! Plays a massive role in @MoffittHemOnc fellows' education year-long! We know no one more deserving for the award
Nikesh Shah, MD retweeted
An absolutely maddening, but telling excerpt from the @propublica report on UnitedHealthcare denying a patient's much-needed ulcerative colitis treatment 👇
Often, the arbiters of what is "clinically appropriate" don't have subspecialty expertise or up-to-date practice patterns!
Pirtobrutinib FDA approved for relapsed/refractory mantle cell lymphoma after prior btk inhibitor! #lymsm fda.gov/drugs/resources-info…
Don't forget to check out the excellent ASH educational series. Nice to have everything in one place to reference.
Wonderful reviews by @anitajkumarMD and @ChrisRFlowersMD, among others
ashpublications.org/hematolo…
Nikesh Shah, MD retweeted
Chemo-free combination of ponatinib + blinatumomab is potentially curative in Ph+ ALL w/o need for intensive chemo or allo-SCT. This is new standard of care in Ph+ ALL.
Jabbour, Short, Kantarjian of @MDAndersonNews #Leukemia authors.elsevier.com/a/1g5k1… via @TheLancetHaem
#leusm
MCL TRIANGLE Study- well-deserved Plenary at #ASH22!
Young pts w new MCL- RCHOP/DHAP+auto in CR1 is not superior to RCHOP/DHAP+ibrutinib ->I maint.
Interestingly, receipt of rituximab maintenance did not impact outcomes, though this wasn't randomized.
Will be interesting to compare w/ ECOG-ACRIN 4151 results.
#lymsm
Nikesh Shah, MD retweeted
BREAKING NEWS!🔥
FDA approves cobimetinib for histiocytic neoplasms! This is a huge victory for this underserved population, and highlights that clinical trials are feasible for ultra-rare diseases. bit.ly/3Dn4Lwk @Histiocytosis @ECDGA @MSK_Histio @HistiocyteSoc